单位(元)汇添富创新医药混合A(006113)利润表 |
| 报告期 |
2025/6/30 |
2024/12/31 |
2024/6/30 |
2023/12/31 |
| 收入 |
1,812,151,970 |
-1,326,351,282 |
-1,441,708,459 |
-1,561,319,504 |
| 利息收入 |
1,602,440 |
2,988,204 |
1,183,255 |
3,391,004 |
| 其中:存款利息收入 |
914,795 |
2,491,616 |
1,183,255 |
3,391,004 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
687,644 |
496,587 |
- |
- |
| 投资收益 |
144,293,966 |
-1,556,783,284 |
-1,074,952,589 |
-1,300,011,715 |
| 其中:股票投资收益 |
127,791,576 |
-1,620,468,880 |
-1,120,773,532 |
-1,371,563,077 |
| 基金投资收益 |
- |
- |
- |
- |
| 债券投资收益 |
1,113,721 |
11,150,851 |
8,982,752 |
8,225,875 |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
- |
- |
- |
- |
| 股利收益 |
15,388,668 |
52,534,745 |
36,838,191 |
63,325,487 |
| 公允价值变动收益 |
1,640,545,049 |
226,803,084 |
-368,187,078 |
-266,539,823 |
| 汇兑收益 |
- |
- |
- |
- |
| 其他收入 |
25,710,516 |
640,714 |
247,954 |
1,841,030 |
| 费用 |
41,597,085 |
74,802,714 |
39,796,043 |
125,868,563 |
| 管理人报酬 |
35,126,052 |
63,893,109 |
33,997,520 |
107,661,764 |
| 托管费 |
5,854,342 |
10,648,852 |
5,666,253 |
17,943,627 |
| 销售服务费 |
437,021 |
- |
- |
- |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
- |
- |
- |
- |
| 其中:卖出回购金融资产支出 |
- |
- |
- |
- |
| 其他费用 |
179,652 |
260,753 |
132,270 |
263,172 |
| 利润总额 |
1,770,554,885 |
-1,401,153,996 |
-1,481,504,503 |
-1,687,188,067 |
| 减:所得税费用 |
- |
- |
- |
- |
| 净利润 |
1,770,554,885 |
-1,401,153,996 |
-1,481,504,503 |
-1,687,188,067 |
*注:新浪财经提醒:以上数据由合作伙伴提供,仅供参考,交易请以正式公告数据为准。